TY - JOUR
T1 - Association of virus load, CD4 cell count, and treatment with clinical progression in human immunodeficiency virus-infected patients with very low CD4 cell counts
AU - EuroSIDA Study Group Members
AU - Miller, Veronica
AU - Phillips, Andrew N.
AU - Clotet, Bonaventura
AU - Mocroft, Amanda
AU - Ledergerber, Bruno
AU - Kirk, Ole
AU - Ormaasen, Vidar
AU - Gargalianos-Kakolyris, Panagiotis
AU - Vella, Stefano
AU - Lundgren, Jens D.
AU - Hermans, P.
AU - Sommereijns, B.
AU - Colebunders, R.
AU - Machala, L.
AU - Rozsypal, H.
AU - Nielsen, J.
AU - Lundgren, J.
AU - Benfield, T.
AU - Kirk, O.
AU - Gerstoft, J.
AU - Katzenstein, T.
AU - Røge, B.
AU - Skinhøj, P.
AU - Pedersen, C.
AU - Katlama, C.
AU - Riviére, C.
AU - Viard, J. P.
AU - Saint-Marc, T.
AU - Vanhems, P.
AU - Pradier, C.
AU - Dietrich, M.
AU - Manegold, C.
AU - van Lunzen, J.
AU - Miller, V.
AU - Staszewski, S.
AU - Goebel, F. D.
AU - Salzberger, B.
AU - Rockstroh, Jürgen
AU - Gargalianos, P.
AU - Sambatakou, H.
AU - Perdios, J.
AU - Stergiou, G.
AU - Panos, G.
AU - Boulmetis, G.
AU - Astriti, M.
AU - Banhegyi, D.
AU - Mulcahy, F.
AU - Yust, I.
AU - Turner, D.
AU - Bentwich, Z.
N1 - Funding Information:
Received 30 November 2001; revised 19 March 2002; electronically published 3 July 2002. National and local guidelines were followed to obtain informed consent at participating study centers. Financial support: European Commission (BIOMED); GlaxoSmithKline, Roche, and Boehringer-Ingelheim (unrestricted); Swiss Federal Office for Education and Science (support of Swiss sites). a Present affiliation: George Washington University, School of Public Health and Human Services, Washington, DC. b Study group members are listed after the text. Reprints or correspondence: Dr. Veronica Miller, Forum for Collaborative HIV Research, George Washington University, School of Public Health and Health Services, 2021 K St. NW, Ste. 800, Washington, DC 20009 ([email protected]).
PY - 2002/7/15
Y1 - 2002/7/15
N2 - This study prospectively assessed the impact of treatment modality, virus load, and CD4 cell count of <50 cells/mm3 on human immunodeficiency virus disease progression. The incidence rate of new AIDS disease or death was 54.8 (95% confidence interval, 48.7-59.9) per 100 person-years of follow-up. Independent predictors related to progression were latest CD4 cell count (relative risk [RR], 0.84/10 mm3 higher; P < .0001), latest hemoglobin level (RR, 0.79/g/L higher; P < .0001), Pneumocystis carinii pneumonia prophylaxis (RR, 0.49; P < .0001), latest body mass index (RR, 0.93/kg/m2 higher; P = .002), latest virus load (RR, 1.11/log10 higher; P = .03), and intensity of treatment (RR, 1.82, P = .004; RR 2.27, P < .0001; RR 2.46, P = .0001; RR 2.33 P < .0006;5.10, P < .0001, respectively, for 4, 3, 2, 1, or no drugs vs. ≥5 drugs). Although reverse causality cannot be excluded, more intense antiviral treatment appears to decrease the risk of progression in immunocompromised patients.
AB - This study prospectively assessed the impact of treatment modality, virus load, and CD4 cell count of <50 cells/mm3 on human immunodeficiency virus disease progression. The incidence rate of new AIDS disease or death was 54.8 (95% confidence interval, 48.7-59.9) per 100 person-years of follow-up. Independent predictors related to progression were latest CD4 cell count (relative risk [RR], 0.84/10 mm3 higher; P < .0001), latest hemoglobin level (RR, 0.79/g/L higher; P < .0001), Pneumocystis carinii pneumonia prophylaxis (RR, 0.49; P < .0001), latest body mass index (RR, 0.93/kg/m2 higher; P = .002), latest virus load (RR, 1.11/log10 higher; P = .03), and intensity of treatment (RR, 1.82, P = .004; RR 2.27, P < .0001; RR 2.46, P = .0001; RR 2.33 P < .0006;5.10, P < .0001, respectively, for 4, 3, 2, 1, or no drugs vs. ≥5 drugs). Although reverse causality cannot be excluded, more intense antiviral treatment appears to decrease the risk of progression in immunocompromised patients.
UR - http://www.scopus.com/inward/record.url?scp=0037099450&partnerID=8YFLogxK
U2 - 10.1086/341466
DO - 10.1086/341466
M3 - Article
C2 - 12134254
AN - SCOPUS:0037099450
SN - 0022-1899
VL - 186
SP - 189
EP - 197
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 2
ER -
